Teleukin - Philogen

Drug Profile

Teleukin - Philogen

Alternative Names: F-16-IL-2; F16 IL2 fusion protein

Latest Information Update: 26 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I Acute myeloid leukaemia; Non-small cell lung cancer
  • Discontinued Breast cancer; Haemangiosarcoma; Malignant melanoma

Most Recent Events

  • 26 Feb 2018 Phase-I clinical trials for Non-small cell lung cancer (Combination therapy with nivolumab) in Europe (IV) (Philogen pipeline, February 2018)
  • 08 Sep 2016 Discontinued - Phase-II for Breast cancer (Combination therapy) in Italy (IV)
  • 08 Sep 2016 Discontinued - Phase-II for Haemangiosarcoma (Combination therapy) in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top